A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

Compass Therapeutics has announced top-line data from its ongoing COMPANION-002 trial investigating its antibody-based therapeutic for biliary tract cancer (BTC), tovecimig.

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic ...

Cipla has secured USFDA approval to market a generic cancer treatment, specifically paclitaxel protein-bound particles.

GOG286B reported efficacy findings and new exploratory outcomes on the combination of metformin, paclictaxel, and carboplatin ...

Drug major Cipla on Friday said it has received approval from the US health regulator to market a generic cancer treatment ...

Investigators conducted a 4T1 breast cancer mouse model study to assess whether a combination of Shenhuang plaster, an herbal formula, plus paclitaxel could enhance the anti-tumor effects of ...

Compass Therapeutics (CMPX) announced statistically significant top-line data on the primary efficacy endpoint for COMPANION-002, the Company’s ...

Patients will receive relacorilant in combination with nab-paclitaxel and bevacizumab. "In our pivotal Phase 3 ROSELLA trial, treatment with relacorilant and nab-paclitaxel improved patients ...

Adding afuresertib to paclitaxel did not improve outcomes in patients with platinum-resistant ovarian cancer in a phase 2 trial.

Cipla receives USFDA approval for generic protein-bound paclitaxel, a cancer treatment drug, expected to launch soon.